Page last updated: 2024-08-25

clarithromycin and zanamivir

clarithromycin has been researched along with zanamivir in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Ishii, H; Ishimoto, H; Kadota, JI; Mukae, H; Nishida, C; Noguchi, S; Sakamoto, N; Umeki, K; Yamasaki, K; Yatera, K1
Chan, KH; Hung, IFN; Kao, RYT; Lee, ACY; Li, C; To, KKW; Yuen, KY; Zhang, AJX; Zhang, RR; Zhu, H1

Other Studies

4 other study(ies) available for clarithromycin and zanamivir

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
The additive effect of clarithromycin on influenza A infection in the elderly patients and patients with comorbid diseases.
    Respiratory investigation, 2017, Volume: 55, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antiviral Agents; Clarithromycin; Cohort Studies; Comorbidity; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Influenza A virus; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Phosphorous Acids; Pneumonia; Prospective Studies; Treatment Outcome; Zanamivir

2017
Triple combination of FDA-approved drugs including flufenamic acid, clarithromycin and zanamivir improves survival of severe influenza in mice.
    Archives of virology, 2018, Volume: 163, Issue:9

    Topics: Animals; Antiviral Agents; Clarithromycin; Drug Approval; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Flufenamic Acid; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Interleukin-1beta; Lung; Mice; Mice, Inbred BALB C; Tumor Necrosis Factor-alpha; United States; United States Food and Drug Administration; Zanamivir

2018